<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511130</url>
  </required_header>
  <id_info>
    <org_study_id>MRKR-19-401</org_study_id>
    <nct_id>NCT04511130</nct_id>
  </id_info>
  <brief_title>Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant</brief_title>
  <official_title>A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marker Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marker Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and&#xD;
      efficacy of MT-401 administration to patients with AML, who have received their first&#xD;
      allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is in patients aged ≥18 years old undergoing or having relapsed after their first&#xD;
      allogeneic HSCT (matched sibling, matched unrelated donor, or haploidentical transplants) for&#xD;
      AML.&#xD;
&#xD;
      Potential patients for the study may be screened/enrolled:&#xD;
&#xD;
      • Prior to their first allogeneic HSCT.&#xD;
&#xD;
      or&#xD;
&#xD;
      • Patients experiencing their first relapse post-allogeneic transplant.&#xD;
&#xD;
      Patients eligible for the study will be placed into one of two groups:&#xD;
&#xD;
        -  Adjuvant (Group 1): Patients screened prior to their HSCT with CR without minimal&#xD;
           residual disease (CRMRD-) at 90 days post transplant will be randomized (1:1) in an&#xD;
           unblinded fashion to:&#xD;
&#xD;
             -  MT-401 (Arm A)&#xD;
&#xD;
             -  SOC (Arm B)&#xD;
&#xD;
        -  Active Disease: (Group 2): Patients meeting the following criteria will be assigned to&#xD;
           Group 2 and will receive MT 401:&#xD;
&#xD;
             -  Patients who experience relapse (patients with MRD [MRD+] or frank relapse) at or&#xD;
                prior to post-transplant Day 90&#xD;
&#xD;
             -  Patients in Arm B of Group 1 (SOC) who develop relapse (MRD+ or frank relapse)&#xD;
                post-HSCT (crossover patients)&#xD;
&#xD;
             -  Patients who do not consent prior to HSCT but are experiencing their first relapse&#xD;
                (MRD+ or frank relapse) and have the same donor available for manufacturing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Lead-In</measure>
    <time_frame>Baseline through Cycle 1 (28 Days)</time_frame>
    <description>Number of participants with MT-401 Dose Limiting Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Adjuvant Group</measure>
    <time_frame>Up to 24 months after the first participant is randomized</time_frame>
    <description>Relapse Free Survival (RFS), defined as the time from randomization to first disease recurrence or death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Active Disease Group</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Complete Remission (CR), per European LeukemiaNet (ELN) 2017 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Active Disease Group</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Duration of CR (DOCR), defined as the time from the first observation of CR through disease recurrence or death from any cause</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>MT-401 following HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with MT-401 at 90 days following HSCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care following HSCT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-401 following relapse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with MT-401 following relapse after first HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-401</intervention_name>
    <description>MT-401 (zelenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.</description>
    <arm_group_label>MT-401 following HSCT</arm_group_label>
    <arm_group_label>MT-401 following relapse</arm_group_label>
    <other_name>zelenoleucel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. First allogeneic HSCT, in ≤ CR2, and MRD negative prior to transplant (including&#xD;
             matched sibling, MUD with at least 6 of 8 HLA markers, or haploidentical with at least&#xD;
             5 of 10 HLA markers) as:&#xD;
&#xD;
               -  Adjuvant therapy for AML (Group 1) at 90 days (±10 days) post-HSCT defined as&#xD;
                  patients with CRMRD; or&#xD;
&#xD;
               -  Treatment for refractory/relapsed AML (first relapse post-HSCT) when disease&#xD;
                  occurs after transplant (Group 2) defined as&#xD;
&#xD;
                    -  First relapse (MRD+ or frank relapse) post-HSCT&#xD;
&#xD;
                    -  Patients in Arm 1B (SOC) who experience first relapse (MRD+ or frank&#xD;
                       relapse) post HSCT&#xD;
&#xD;
               -  Safety Lead-in defined as patients who fit all the criteria for Group 2 only&#xD;
&#xD;
          2. Are ≥18 years of age&#xD;
&#xD;
          3. Karnofsky/Lansky score of ≥60&#xD;
&#xD;
          4. Life expectancy ≥12 weeks&#xD;
&#xD;
          5. Adequate blood, liver, and renal function&#xD;
&#xD;
               -  Blood: Hemoglobin ≥7.0 g/dL (can be transfused)&#xD;
&#xD;
               -  Liver: Bilirubin ≤2X upper limit of normal; aspartate aminotransferase ≤3X upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Renal: Serum creatinine ≤2X upper limit of normal or measured or calculated&#xD;
                  creatinine clearance ≥45mL/min&#xD;
&#xD;
        7. Patients are allowed to be on experimental conditioning regimens prior to transplant if&#xD;
        no planned maintenance therapy post-transplant.&#xD;
&#xD;
        8. In Group 2, patients may receive bridging therapy at the investigators' discretion in&#xD;
        situations where MT-401 is not ready for administration or the treating physician believes&#xD;
        the patient would benefit&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Clinically significant or severely symptomatic intercurrent infection&#xD;
&#xD;
          2. Pregnant or lactating&#xD;
&#xD;
          3. For Group 1, anti-neoplastic therapy after HSCT and prior to or during dosing of&#xD;
             MT-401&#xD;
&#xD;
          4. For Group 2, concomitant anti-neoplastic therapy during or after dosing of MT-401&#xD;
&#xD;
          5. Evidence of acute or chronic GVHD ≥Grade 2 (exception: acute or chronic Grade 2 GVHD&#xD;
             of skin allowed if stable) within one week prior to receiving MT-401&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mythili Koneru, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Marker Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mythilli Koneru, MD, PhD</last_name>
    <phone>713.400.6400</phone>
    <email>mkoneru@markertherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald Garrett</last_name>
    <phone>713.400.6400</phone>
    <email>ggarrett@markertherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankit Vachhani, MD</last_name>
      <phone>205-934-6770</phone>
      <email>pvachhani@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Stephens, RN</last_name>
      <phone>205.975.2028</phone>
      <email>lmeggs@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pankit Vachhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukaib Arslan, MD</last_name>
      <phone>877-467-3411</phone>
      <email>sarslan@coh.org</email>
    </contact>
    <investigator>
      <last_name>Shukaib Arslan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Urdiales</last_name>
      <phone>813-745-1218</phone>
      <email>Maria.Urdiales@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Burton, RN</last_name>
      <phone>813.745.1537</phone>
      <email>Michelle.Burton@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nelli Bejanyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>303222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Trumbull</last_name>
      <phone>404-778-3969</phone>
      <email>ashley.lynn.trumbull@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Corey Williams</last_name>
      <phone>404-251-2014</phone>
      <email>williams2@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Blum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongtao Liu, MD</last_name>
      <phone>773-702-0589</phone>
      <email>hliu2@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hongtao Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarida Silverman, MD</last_name>
      <phone>319-356-1616</phone>
      <email>margarida-silverman@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Parrott, RN</last_name>
      <phone>319.353.6347</phone>
      <email>karen-parrott@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Margarida Silverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Frigault, MD</last_name>
      <phone>617-643-6175</phone>
      <email>mfrigault@partners.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Frigault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markenya Mirander</last_name>
      <email>mmirande@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Joel Victor</last_name>
      <email>jovictor@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alejandro Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine | NewYork-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Mitto</last_name>
      <phone>917-755-0286</phone>
      <email>am9073@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alina Surkanova</last_name>
      <email>als2086@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jing-Mei Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniella Burnetta</last_name>
      <email>burnetd2@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Elko, MPAS, PA-C</last_name>
      <phone>646.608.3851</phone>
      <phone_ext>pager 3456</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Boglarka Gyurkocza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navneet Majhail, MD</last_name>
      <phone>216-444-2199</phone>
      <email>majhain@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Navneet Majhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica M McCarty</last_name>
      <phone>713-745-5228</phone>
      <email>jmmccarty@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Betul Oran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

